drugset / Trial / NCT01458639

Compare Technegas Ventilation-Perfusion SPECT and Xenon Ventilation-Perfusion Planar Imaging for Pulmonary Embolism

NCT01458639

Phase 3 Terminated 18 enrolled Cyclomedica Australia PTY Limited
Non-randomizedCrossoverSingle-blindDiagnostic

Summary

Phase 3 within-subject trial of Technegas V/Q SPECT and Tc-99m macro-aggregated albumin (MAA) imaging compared to Xenon-133 V/Q planar and Tc-99m macroaggregate of albumin (MAA) imaging for the diagnosis of Pulmonary Embolism (PE).

Timeline

Start
2012-08
Primary completion
2015-06
Completion
2015-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Technegas Diagnostic / imaging agent 40.7 mbq
Comparator Xenon-133 Diagnostic / imaging agent
Background Technetium 99m MAA Unknown

Indications